Cardiovascular risk

Assessing cardiovascular risk

Optimal cardiovascular risk assessment allows doctors to adjust treatment in high-risk patients at an early stage.

Cardiovascular Risk

Cardiovascular diseases include a number of conditions related to the heart and the vascular network. Examples of these are hypertension, dyslipidemia, stroke, atherosclerosis, thrombosis and coronary artery disease. These are interrelated indications, which tend to be linked in a complex cascade meaning one may lead to another if not treated properly. Risk factors such as dyslipidemia and diabetes, among others, may cause cardiovascular disease.
Patients with diabetes, renal disease and/or atherosclerosis may have an increased cardiovascular risk. This makes it important to assess the cardiovascular risk of these patients to be able to change treatment in high-risk patients as soon as possible.
The heart and the cardiovascular system


The extensively validated AGE Reader provides an immediate and non-invasive cardiovascular risk prediction. The AGE Reader is very easy to use measurement and therefore leads to clinically valuable extra information.

The AGE Reader dramatically improves the cardiovascular risk prediction for diabetes, renal failure, and atherosclerosis patients. The method is convenient, easy to use and validated.

Read more about cardiovascular risk in:

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu - connect
Non-invasive cardiovascular risk assessment
The AGE Reader mu - connect is the latest generation AGE Reader that combines a high measurement quality standard with an innovative design. The AGE Reader mu is the perfect tool for physicians that want to improve the personalized care of their patients.
Read more » Read more »
About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.